European shares were muted on Tuesday as healthcare sector gains powered by heavyweight Novo Nordisk clinching US approval of its weight loss pill were offset by losses in consumer-facing shares. The pan-European STOXX 600 was up 0.2% at 587.91 by 0808 GMT. Major regional markets were largely subdued, with benchmark indexes in London and France little changed. Shares of Novo Nordisk advanced 5.8% after the US Food and Drug Administration approved its weight-loss pill on Monday, giving the drugmaker a major competitive advantage in the increasingly lucrative weight management market. The healthcare sector jumped 0.8%, the most among peers. Consumer discretionary shares were the biggest weights, with some luxury stocks such as Richemont falling. Energy slipped 0.1%, after logging four consecutive sessions of gains. Third-quarter US GDP figures, which are expected to show that the US economy had continued to grow strongly, will be on the radar in an otherwise data-light week.